Clinical Trial Update: Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab

View source ↗

Summary

This clinical trial update reports outcomes for diabetic macular edema patients who switched from bevacizumab and/or ranibizumab to aflibercept.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• Avastin (bevacizumab)
• EYLEA (Aflibercept)
• Lucentis (ranibizumab)

Snippet

Sponsor: Stanford University | Conditions: Diabetic Macular Edema | Status: COMPLETED